ADPT vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADPT's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 1/9 indicates extreme weakness, with no positive signals in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative ROE (-27.82%), negative operating margin (-17.82%), and high debt/equity (0.93) suggest significant distress risk. Despite strong revenue growth (51% YoY) and a history of earnings surprises, the stock trades at a forward P/E of -48.78, reflecting deep losses and speculative valuation. Insider selling totaling $12.73M in six months further undermines confidence, signaling potential internal skepticism about near-term prospects.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADPT vs MRK: Head-to-Head Comparison
This page compares Adaptive Biotechnologies Corporation (ADPT) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.